Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | 9.71% | |
Lower Bollinger Band Walk | Weakness | 9.71% | |
Wide Bands | Range Expansion | 9.71% | |
Oversold Stochastic | Weakness | 9.71% | |
New 52 Week Closing Low | Bearish | 10.66% | |
Lower Bollinger Band Walk | Weakness | 10.66% | |
New 52 Week Low | Weakness | 10.66% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 17 hours ago |
1.5x Volume Pace | about 17 hours ago |
Outside Day | about 17 hours ago |
Up 5% | about 17 hours ago |
60 Minute Opening Range Breakout | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 35.06 |
52 Week Low | 13.96 |
Average Volume | 396,916 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 24.16 |
20-Day Moving Average | 20.06 |
10-Day Moving Average | 17.18 |
Average True Range | 1.53 |
RSI (14) | 32.89 |
ADX | 48.48 |
+DI | 10.61 |
-DI | 38.21 |
Chandelier Exit (Long, 3 ATRs) | 20.27 |
Chandelier Exit (Short, 3 ATRs) | 18.55 |
Upper Bollinger Bands | 26.52 |
Lower Bollinger Band | 13.61 |
Percent B (%b) | 0.23 |
BandWidth | 64.37 |
MACD Line | -2.54 |
MACD Signal Line | -2.22 |
MACD Histogram | -0.3279 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 19.42 | ||||
Resistance 3 (R3) | 19.12 | 17.88 | 18.95 | ||
Resistance 2 (R2) | 17.88 | 17.16 | 18.03 | 18.80 | |
Resistance 1 (R1) | 17.25 | 16.72 | 17.56 | 17.55 | 18.64 |
Pivot Point | 16.01 | 16.01 | 16.16 | 16.16 | 16.01 |
Support 1 (S1) | 15.37 | 15.29 | 15.69 | 15.67 | 14.58 |
Support 2 (S2) | 14.13 | 14.85 | 14.28 | 14.42 | |
Support 3 (S3) | 13.50 | 14.13 | 14.27 | ||
Support 4 (S4) | 13.80 |